Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has provided an update.
On March 23, 2026, Pulse Biosciences, Inc. granted its Chief Technology Officer, Darrin R. Uecker, 100,000 restricted stock units as recognition for his continued leadership in developing the company’s atrial fibrillation treatment technologies. The award, which will vest in full on the third anniversary of the grant date under the firm’s equity incentive plan, underscores the company’s strategy of tying executive incentives to long‑term product development milestones and shareholder value creation.
The grant structure aligns Uecker’s compensation with sustained progress in Pulse Biosciences’ core atrial fibrillation program, signaling the board’s confidence in his stewardship of this critical growth area. For investors and other stakeholders, the move highlights the importance of maintaining continuity in technical leadership as the company works to advance and potentially commercialize its cardiac treatment platform.
The most recent analyst rating on (PLSE) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, large losses, and accelerating cash burn). Offsetting factors include strong technical momentum and encouraging clinical/regulatory progress discussed on the earnings call and in recent updates, though valuation remains constrained by ongoing losses and funding needs.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a medical technology company focused on developing products for the treatment of atrial fibrillation. The company’s efforts center on advancing its product development programs in cardiac ablation, where leadership in technology execution is positioned as a key driver of future growth and competitiveness.
Average Trading Volume: 333,740
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.46B
For an in-depth examination of PLSE stock, go to TipRanks’ Overview page.